Literature DB >> 1682737

p53 mutation in hepatocellular carcinoma after aflatoxin exposure.

M Ozturk1.   

Abstract

Mutations of the p53 gene are found in hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Specific mutations might reflect exposure to specific carcinogens and we have screened HCC samples from patients in 14 different countries to determine the frequency of a hotspot mutation at codon 249 of the tumour suppressor p53 gene. We detected mutations in 17% of tumours (12/72) from four countries in south Africa and the southeast coast of Asia. There was no codon 249 mutation in 95 specimens of HCC from other geographical locations including North America, Europe, Middle East, and Japan. Worldwide, the presence of the codon 249 mutation in HCCs correlated with high risk of exposure to aflatoxins and the hepatitis B virus (HBV). Further studies were completed in two groups of HBV-infected patients at different risks of exposure to aflatoxins. 53% of patients (8/15) from Mozambique at high risk of aflatoxin exposure had a tumour with a codon 249 mutation, in contrast with 8% of patients from Transkei (1/12) who were at low risk. HCC is an endemic disease in Mozambique and accounts for up to two thirds of all tumours in men. A codon 249 mutation of the p53 gene identifies an endemic form of HCC strongly associated with dietary aflatoxin intake.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1682737     DOI: 10.1016/0140-6736(91)92236-u

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  71 in total

Review 1.  The clonal origin and clonal evolution of epithelial tumours.

Authors:  S B Garcia; M Novelli; N A Wright
Journal:  Int J Exp Pathol       Date:  2000-04       Impact factor: 1.925

2.  Aflatoxin sufferer and p53 gene mutation in hepatocellular carcinoma.

Authors:  Zhuo-Lin Deng; Yun Ma
Journal:  World J Gastroenterol       Date:  1998-02       Impact factor: 5.742

3.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.

Authors:  Hyun Goo Woo; Xin Wei Wang; Anuradha Budhu; Yun Hee Kim; So Mee Kwon; Zhao-You Tang; Zongtang Sun; Curtis C Harris; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2010-11-19       Impact factor: 22.682

Review 4.  Genetics of hepatocellular carcinoma.

Authors:  Andreas Teufel; Frank Staib; Stephan Kanzler; Arndt Weinmann; Henning Schulze-Bergkamen; Peter-R Galle
Journal:  World J Gastroenterol       Date:  2007-04-28       Impact factor: 5.742

5.  Endomyocardial fibrosis and hepatocellular carcinoma in Inhambane Province in Mozambique.

Authors:  Eloi Marijon
Journal:  Can J Cardiol       Date:  2007-03-01       Impact factor: 5.223

Review 6.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

7.  Separate origins of hepatitis B virus surface antigen-negative foci and hepatocellular carcinomas in transgenic HBsAg (alb/psx) mice.

Authors:  Dana R Crawford; Stephanie Ostrowski; Dilip Vakharia; Zoran Ilic; Stewart Sell
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

Review 8.  Mechanisms underlying aflatoxin-associated mutagenesis - Implications in carcinogenesis.

Authors:  Amanda K McCullough; R Stephen Lloyd
Journal:  DNA Repair (Amst)       Date:  2019-03-07

9.  Genetic heterogeneity of hepatocellular carcinoma.

Authors:  H Unsal; C Yakicier; C Marçais; M Kew; M Volkmann; H Zentgraf; K J Isselbacher; M Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-18       Impact factor: 11.205

10.  249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients.

Authors:  Jeronimo A Nogueira; Suzane K Ono-Nita; Marcelo E Nita; Marcelo M T de Souza; Eliane P do Carmo; Evandro S Mello; Cristovan Scapulatempo; Denise C Paranaguá-Vezozzo; Flair J Carrilho; Venancio A F Alves
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.